U.S. stock movement | Novo Nordisk rises over 2% as results from Phase III trial of new generation weight loss drug Cagrilintide are positive
I'm PortAI, I can summarize articles.
Novo Nordisk's stock price rose more than 2% on Tuesday, closing at $57.12. The company's new weight loss drug Cagrilintide performed well in phase three clinical trials, with patients losing an average of 11.8% of their weight after 68 weeks, compared to just 2.3% in the placebo group. Cagrilintide is a long-acting glucagon-like peptide that effectively increases satiety. Novo Nordisk's Chief Scientific Officer expressed excitement about the trial results and looks forward to further validating its potential
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments